NEW YORK (GenomeWeb) – Illumina said on Sunday that it has launched a new company called Grail, which will develop a next-generation sequencing blood-based screening test for early cancer detection.

Grail has raised more than $100 million in a Series A financing round from Arch Venture Partners and Illumina, which contributed $40 million. Bezos Expeditions, Bill Gates, and Sutter Hill Ventures also invested in Grail.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.